SMS/Eclipsys
This article was originally published in The Gray Sheet
Executive Summary
Health information systems and services provider Shared Medical Systems rejects a $2 bil. merger proposal from health care information solutions firm Eclipsys and remains "uninterested in a combination," SMS states March 3. The proposed merger, which would value SMS at $67 per share, represents a 75% premium over the stock's March 2 closing price of $38.25. The proposal "represents the most recent in a series of efforts" by Eclipsys Chairman Harvey Wilson "to cause SMS, in effect, to acquire his company, under circumstances in which he assumes management control," SMS explains. SMS recorded 1999 revenues of $1.2 bil. while Eclipsys had revenues of $249 mil
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.